Coronavirus: UK begin COVID-19 clinical trials | Fieldfisher
Skip to main content

Coronavirus: UK begin COVID-19 clinical trials



United Kingdom

The UK Government announced this week that public funding would be given to support two clinical trial projects investigating vaccines to prevent the spread of the COVID-19 coronavirus. According to Health Secretary Matt Hancock, £22.5 million will be donated to Imperial College London to support Phase II clinical trials that will assess a sample of several thousand patients and begin work on an ever larger Phase III trial.

Additionally, £20 million will be granted to a team at the University of Oxford to fund clinical trials for their vaccine with trials commencing today. The government will also invest in manufacturing capabilities to produce either of these vaccines, once demonstrated effective and safe in clinical trials.
According to the World Health Organisation (WHO), more than 70 COVID-19 vaccines are in development worldwide but the UK now joins only the United States (two studies) and China in beginning human trials.
There are not currently any licensed vaccines for COVID-19 but the clinical trials will enable scientific researchers to assess if healthy people can be protected from COVID-19 and provide valuable information on the vaccines safety and ability to generate good immune responses against the virus.

Earlier this month we wrote about the global race to find a vaccine, click here to read our overview on how clinical trials for vaccine works.
We are all navigating uncharted waters as business and society faces up to the impact of COVID-19.  We very much hope you and your loved ones remain in good health. 

 Please be assured that Fieldfisher is continuing to work with clients to navigate COVID-19 related issues and on business as usual needs.  Do get in touch with us if you would like to chat anything through.


Sign up to our email digest

Click to subscribe or manage your email preferences.